The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection

Journal of Hepatology

Volumn 63, Issue 2, 2015, Pages 320-328

  Gane, Edward J ^a   Lim, Young Suk ^b   Gordon, Stuart C ^c   Visvanathan, Kumar ^d   Sicard, Eric ^e   Fedorak, Richard N ^f   Roberts, Stuart ^g   Massetto, Benedetta ^h   Ye, Zhishen ^h   Pflanz, Stefan ^h   Garrison, Kimberly L ^h   Gaggar, Anuj ^h   Subramanian, G Mani ^h   McHutchison, John G ^h   Kottilil, Shyamasundaran ⁱ   Freilich, Bradley ^j   Coffin, Carla S ^k   Cheng, Wendy ^l   Kim, Yoon Jun ^m  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b University of Ulsan College of Medicine   (South Korea)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Algorithme Pharma   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g ALFRED HEALTH   (Australia)

^h GILEAD SCIENCES   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j Kansas City Gastroenterology and Hepatology   (United States)

^k UNIVERSITY OF CALGARY   (Canada)

^l ROYAL PERTH HOSPITAL   (Australia)

^m Seoul National University   (South Korea)

more..

Author keywords

HBsAg; Hepatitis B virus; Immune response; TLR

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ENTECAVIR; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON STIMULATED GENE FACTOR 15; LAMIVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; MESSENGER RNA; PLACEBO; TELBIVUDINE; TENOFOVIR; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; VESATOLIMOD; VIRUS DNA; ANTIVIRUS AGENT; GS-9620; PTERIDINE DERIVATIVE; TLR7 PROTEIN, HUMAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CHILL; CHRONIC HEPATITIS B; CONTROLLED STUDY; CONTUSION; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOREARM FRACTURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE EXPRESSION; HEADACHE; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE A; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS B VIRUS GENOTYPE D; HEPATITIS B VIRUS GENOTYPE E; HUMAN; LEUKOCYTE COUNT; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPHIL COUNT; NONHUMAN; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; ADULT; AGED; AGONISTS; CLINICAL TRIAL; FOLLOW UP; GENETICS; GENOTYPE; HEPATITIS B, CHRONIC; IMMUNOLOGY; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PTERIDINES; RETROSPECTIVE STUDIES; TOLL-LIKE RECEPTOR 7; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84935451137     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.02.037     Document Type: Article

References (34)

1. Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-2219.
2. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011;8:275-284.
3. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012;61:1754-1764.
4. Maini ML, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol 2010;52:616-619.
5. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006;7:131-137.
6. Sadler AJ. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008;8:559-568.
7. Belloni L, Allweiss L, Guerrieri F, et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012;122:529-537.
8. Tel J, Sittig SP, Blom RAM, et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol 2013;191:5005-5012.
9. Bekeredjian-Ding IB, Wagner M, Hornung V, et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005;174:4043-4050.
10. Fosdick A, Zheng J, Pflanz S, et al. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel TLR7 agonist, demonstrates ISG induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther 2014;348:96-105.
11. Lopatin U, Wolfgang G, Tumas D, et al. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral toll-like receptor 7 agonist. Antivir Ther 2013;18:409-418.
12. Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013;144:1508-1517.
13. Menne S, Tennant BC, Liu KH, et al. Antiviral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. In: 46th annual meeting of the European Association for the Study of the Liver; March 30-April 3, 2011; Berlin, Germany; poster 170.
14. Shaffer A, Hubbard J, Townsend K, et al. Serum-based assay accurately detects single nucleotide polymorphisms of IL28B and SOCS3 in HIV/ hepatitis C virus-coinfected subjects. AIDS Res Hum Retroviruses 2014;30:792-795.
15. Schott E, Witt H, Neumann K, et al. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-abased therapy. J Viral Hepat 2008;15:71-78.
16. Sawhney R, Visvanathan K. Polymorphisms of toll-like receptors and their pathways in viral hepatitis. Antivir Ther 2011;16:443-458.
17. Howell J, Angus P, Gow P, Visvanathan K. Toll-like receptors in hepatitis C infection: implications for pathogenesis and treatment. Gastroenterol Hepatol 2013;28:766-776.
18. Shen N, Fu Q, Deng Y, et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A 2010;107:15838-15843.
19. Yue M, Feng L, Tang S, et al. Sex-specific association between X-linked tolllike receptor 7 with the outcomes of hepatitis C virus infection. Gene 2014;548:244-250.
20. Xu HC, Grusdat M, Pandyra AA, et al. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity 2014;40:949-960.
21. Crouse J, Bedenikovic G, Wiesel M, et al. Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity 2014;40:961-973.
22. Menne S, Tumas DB, Liu KH, et al. Sustained efficacy and seroconversion with the toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B. J Hepatol 2015;62:1237-1245.
23. Micco L, Peppa D, Loggi E, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 2013;58:225-233.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-408.
25. García-García I, González-Delgado CA, Valenzuela-Silva CM, et al. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. BMC Pharmacol 2010;10:15.
26. EASL. Clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
27. Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012;143:963-973.
28. Birmachu W, Gleason RM, Bulbulian BJ, Riter CL, Vasilakos JP, Lipson KE, et al. Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists. MBC Immunol 2007;12:8-26.
29. Jaruga B, Hong F, Kim WH, Gao B. IFN-gamma/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. Am J Physiol Gastrointest Liver Physiol 2004;287:G1044-G1052.
30. Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res 2011;317:620-631.
31. Oo YH, Shetty S, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. Dig Dis 2010;28:31-44.
32. Jaroszewicz J, Ho H, Markova A, et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 2011;16:915-924.
33. Wang Y, Zhao C, Zhang L, et al. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients. Antiviral Res 2014;103:51-59.
34. Campbell JA, Lenschow DJ. Emerging roles for immunomodulatory functions of free ISG15. J Interferon Cytokine Res 2013;33:728-738.